WO2010089259A3 - Sustained release composition containing quetiapine - Google Patents
Sustained release composition containing quetiapine Download PDFInfo
- Publication number
- WO2010089259A3 WO2010089259A3 PCT/EP2010/051098 EP2010051098W WO2010089259A3 WO 2010089259 A3 WO2010089259 A3 WO 2010089259A3 EP 2010051098 W EP2010051098 W EP 2010051098W WO 2010089259 A3 WO2010089259 A3 WO 2010089259A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sustained release
- composition containing
- release composition
- pharmaceutical composition
- containing quetiapine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Abstract
The present invention is directed to a sustained release pharmaceutical composition containing quetiapine, a pharmaceutically acceptable salt or a derivative thereof, which allows a once-a-day administration of said sustained release pharmaceutical composition to a patient in need thereof. The present invention is further directed to the use of this composition for the treatment of schizophrenia and acute manic episodes associated with bipolar I disorder, and to a process for preparing the pharmaceutical composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09151996 | 2009-02-04 | ||
EP09151996.7 | 2009-02-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010089259A2 WO2010089259A2 (en) | 2010-08-12 |
WO2010089259A3 true WO2010089259A3 (en) | 2011-07-07 |
Family
ID=42060688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/051098 WO2010089259A2 (en) | 2009-02-04 | 2010-01-29 | Sustained release composition containing quetiapine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010089259A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201008261A1 (en) * | 2010-10-08 | 2012-04-24 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Controlled release quetiapine formulations |
WO2014155387A1 (en) * | 2013-03-24 | 2014-10-02 | Tushar Patel | Extended release dosage forms of quetiapine salts |
CN103315973B (en) * | 2013-05-24 | 2014-05-07 | 杭州和正医药有限公司 | Quetiapine osmotic pump controlled release preparation |
CN104688709A (en) * | 2015-03-24 | 2015-06-10 | 北京世桥生物制药有限公司 | Fumaric acid quetiapine composition sustained-release tablet and preparing method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
WO2005041935A1 (en) * | 2003-10-21 | 2005-05-12 | Alpharma, Inc. | Pharmaceutical formulations containing quetiapine |
WO2007086079A2 (en) * | 2006-01-25 | 2007-08-02 | Astron Research Limited | Sustained release dosage form of phenothiazine derivatives containing channelizer |
WO2008060228A1 (en) * | 2006-11-17 | 2008-05-22 | Astrazeneca Ab | Extended release formulations comprising quetipine and methods for their manufacture |
WO2008090569A1 (en) * | 2007-01-25 | 2008-07-31 | Panacea Biotec Ltd | Modified release pharmaceutical composition and a process of making the same |
EP2153834A2 (en) * | 2008-08-07 | 2010-02-17 | Farmaprojects, S.A. | Extended release pharmaceutical compositions comprising quetiapine salts |
WO2010028794A1 (en) * | 2008-09-10 | 2010-03-18 | Alfred E. Tiefenbacher Gmbh & Co. Kg | Retard tablets containing quetiapine |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
GB8705574D0 (en) | 1987-03-10 | 1987-04-15 | Ici Plc | Preparation of thiazepine compound |
GB9611328D0 (en) | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
US20030185882A1 (en) | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
US7611728B2 (en) | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
CA2613403A1 (en) | 2005-06-29 | 2007-01-04 | Panacea Biotec Ltd. | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof |
-
2010
- 2010-01-29 WO PCT/EP2010/051098 patent/WO2010089259A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
WO2005041935A1 (en) * | 2003-10-21 | 2005-05-12 | Alpharma, Inc. | Pharmaceutical formulations containing quetiapine |
WO2007086079A2 (en) * | 2006-01-25 | 2007-08-02 | Astron Research Limited | Sustained release dosage form of phenothiazine derivatives containing channelizer |
WO2008060228A1 (en) * | 2006-11-17 | 2008-05-22 | Astrazeneca Ab | Extended release formulations comprising quetipine and methods for their manufacture |
WO2008090569A1 (en) * | 2007-01-25 | 2008-07-31 | Panacea Biotec Ltd | Modified release pharmaceutical composition and a process of making the same |
EP2153834A2 (en) * | 2008-08-07 | 2010-02-17 | Farmaprojects, S.A. | Extended release pharmaceutical compositions comprising quetiapine salts |
WO2010028794A1 (en) * | 2008-09-10 | 2010-03-18 | Alfred E. Tiefenbacher Gmbh & Co. Kg | Retard tablets containing quetiapine |
Non-Patent Citations (3)
Title |
---|
"EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF QUETIAPINE", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 1 December 2008 (2008-12-01), XP013128235, ISSN: 1533-0001 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 February 2008 (2008-02-07), XP002633914, Database accession no. 148:151916 * |
KUCHEKAR B ET AL: "preformulation and formulation studies of novel pH independent controlled release drug delivery system of quetiapnie fumarate", JOURNAL OF PHARMACY RESEARCH,, vol. 2, no. 1, 1 January 2009 (2009-01-01), pages 110 - 119, XP008135863, ISSN: 0974-6943 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010089259A2 (en) | 2010-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2371853T3 (en) | Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment | |
SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
MX2020008616A (en) | Sublingual fentanyl spray. | |
MX2020012868A (en) | Methods and compositions for sleep disorders and other disorders. | |
GEP20156366B (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
WO2009017837A3 (en) | Sublingual fentanyl spray | |
NZ589445A (en) | Rasagiline for parkinson's disease modification | |
WO2008149382A8 (en) | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | |
MX2011012122A (en) | Thiophene derivatives. | |
WO2010014690A3 (en) | Medical devices for therapeutic agent delivery | |
MX347106B (en) | Immediate release pharmaceutical compositions comprising oxycodone and naloxone. | |
HK1157337A1 (en) | ||
MX2013012290A (en) | Preparation of high-purity gadobutrol. | |
SG176628A1 (en) | Aminopyrrolidinone derivatives and uses thereof | |
NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
WO2009140341A3 (en) | Atorvastatin compositions | |
NZ594311A (en) | Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration | |
WO2011037976A3 (en) | Pramipexole pharmaceutical formulations | |
WO2010082220A3 (en) | Sustained release pharmaceutical composition of quetiapine and process for preparation thereof | |
EP2241310A3 (en) | Modified release formulations of emoxypine | |
ZA201007391B (en) | Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood | |
MX2012001529A (en) | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators. | |
MX2012001691A (en) | Orally disintegrating compositions of linaclotide. | |
WO2010089259A3 (en) | Sustained release composition containing quetiapine | |
WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10701546 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10701546 Country of ref document: EP Kind code of ref document: A2 |